Tuesday, 4 December 2018

Verstovsek Highlights QoL Benefits With Ruxolitinib in Patients With PV - Targeted Oncology

Verstovsek Highlights QoL Benefits With Ruxolitinib in Patients With PV  Targeted Oncology

Srdan Verstovsek, MD, PhD, discusses the second-line use of ruxolitinib in patients with in PV and additional benefits with the agent as more data become ...



from "phlebotomist" - Google News http://bit.ly/2Rz8PAp
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)